Webinar Postmir Oncologia Radioterápica 📆 Miércoles 30 de abril #mir #oncologíaradioterápica

LINAC vs Cyberknife en SBRT de prostata.

Early results After stereotactic SRT on macroscopic prostate bed relapse (STARR-NCT05455736) suggested safety and effectiveness of this approach! #Estro25, ESTRO ,Niccoló Bertini

#ESTRO25 PROSTATE DART phase II trial(oligomets PSMA+) SBRT+/-Darolutamide Tox & QL results Piet Ost

Oligocare SBRT: la toxicidad es similar en combinación con tto sistémico que con SBRT sola. #ESTRO25

SBRT en tumores de cavidad oral T1T2: toxicidad 9 % osteonecrosis , 13,6% toxicidad grado 3. #ESTRO25

SRS en BM

What about #SABR / #SBRT to the primary tumour in LA-NSCLC? This study just presented at #ESTRO25 has promising survival with little toxicity rates ➡️ improvement in PFS ➡️ trend toward better OS

SBRT + ADT en prostata:

Practical Considerations for the Treatment of Primary Renal Cell Carcinoma With SABR University of Washington Radiation Oncology Fred Hutch Cancer Center Peter Mac Radiation Oncology MD Anderson Cancer Center Dartmouth 🌲 ESTRO ASTRO RANZCR RANZCR Rad Oncology The Royal College of Radiologists the Radiosurgery Society ISRSy

El Título 𝙙𝙚 𝙀𝙨𝙥𝙚𝙘𝙞𝙖𝙡𝙞𝙨𝙩𝙖 𝙐𝙣𝙞𝙫𝙚𝙧𝙨𝙞𝙩𝙖𝙧𝙞𝙤 𝙚𝙣 𝙎𝘽𝙍𝙏 𝙮 𝙍𝙖𝙙𝙞𝙤𝙘𝙞𝙧𝙪𝙜𝙞́𝙖 abordará en el MóduloV la SBRT Pélvica. 🗓️Inicio: 15 de #Septiembre de 2025 Información e inscripciones en: sbrt.es/tasas-e-inscri…

📣New advance in neuro-oncology! OncoAlert PET RANO BM 1.0 criteria standardize #brainmetastases assessment using amino acid PET, enhancing clinical trials & patient care. Read more: 📖 Nature Medicine #btsm nature.com/articles/s4159…

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

New insights on SBRT in recurrent ovarian cancer – now in CTRO: “SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review” 👉 doi.org/10.1016/j.ctro… 🎯 Local control ⏳ Delayed systemic therapy ⚖️ Personalized strategy EORTC

Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib XRT to Oligoprogressive sites increased PFS further by 9.7 months, delaying 2nd Line = clinically meaningful. Subgroup LN + Viscera = Bad Bone = Good

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Don't miss the next FREE #RSSwebinar "Celiac Plexus Radiosurgery: A New Treatment Modality for Pancreatic Cancer Pain" on Tues, 6/17 at noon ET featuring Yaacov Lawrence Md and Leila Tchelebi , moderated by Banu Atalar therss.org/education/webi…